DERM | tickerfilter.com

Fundamental analysis

38%

Profitability 25%

Dept financing 50%

Liquidity 75%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-15.16%

1 Month

22.00%

3 Months

59.27%

6 Months

2.52%

1 Year

52.50%

2 Year

332.62%

Key data

Stock price

$6.10

P/E Ratio

0.00

DAY RANGE

$6.06 - $6.96

EPS

-$0.72

52 WEEK RANGE

$3.20 - $7.29

52 WEEK CHANGE

$39.27

MARKET CAP

81.680 M

YIELD

N/A

SHARES OUTSTANDING

14.727 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-12-2025

BETA

0.92

PUBLIC FLOAT

AVERAGE 10 VOLUME

$141,317

AVERAGE 30 VOLUME

$86,883

Company detail

CEO: Claude Maraoui
Region: US
Website: journeymedicalcorp.com
Employees: 90
IPO year: 2021

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the. treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an. oral doxycycline drug for. adjunctive therapy for severe acne, Ximino, and Exelderm cream for topical use.

DERM - Journey Medical Corp